Impact of Intensive Low-Density Lipoprotein Cholesterol-Lowering Therapy on Coronary Artery Plaques in Acute Coronary Syndrome

被引:3
|
作者
Hirai, Keisuke [1 ]
Kawasaki, Tomohiro [1 ]
Soejima, Toshiya [1 ]
Kajiyama, Kimihiro [1 ]
Fukami, Yurie [1 ]
Asada, Satoshi [1 ]
Haraguchi, Kazuki [1 ]
Fukuoka, Ryota [1 ]
Orita, Yoshiya [1 ]
Umeji, Kyoko [1 ]
Koga, Hisashi [1 ]
Yamabe, Hiroshige [1 ]
机构
[1] Shinkoga Hosp, Cardiovasc Ctr, Div Cardiovasc Med, Kurume, Japan
关键词
coronary computed tomography angiography; lipid lowering therapy; coronary artery plaque; LDL CHOLESTEROL; ANGIOGRAPHY; ATORVASTATIN; METAANALYSIS; PERFORMANCE; GUIDELINES; MANAGEMENT; STENOSIS; SOCIETY; JAPAN;
D O I
10.1016/j.amjcard.2023.07.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute coronary syndrome (ACS) is associated with a high incidence of unstable plaques beyond the culprit lesion, leading to early recurrence of cardiovascular events. Coronary computed tomography angiography (CCTA) can be used to noninvasively observe plaques throughout the coronary arteries. To evaluate the impact of intensive low-density lipopro-tein cholesterol (LDL-C)-lowering therapy on quantitative changes in coronary plaque, assessed using CCTA in a study population with ACS. In total, 81 consecutive patients with ACS who underwent CCTA at discharge and at 1-year follow-up from April 2018 to March 2020 were analyzed. The patients were divided into 2 groups: those who achieved LDL-C <70 mg/100 ml and those who did not. Changes in plaque morphology within and between the 2 groups were compared using CCTA. A total of 198 vessels were analyzed. The calcified plaque volume was significantly increased in the LDL-C <70 group (65.8 & PLUSMN; 80.1 mm3 to 73.6 & PLUSMN; 83.7 mm3, p = 0.007), whereas no significant change was observed in the LDL-C >70 group (106.9 & PLUSMN; 161.7 mm3 to 105.7 & PLUSMN; 137.5 mm3, p = 0.552). Percent change in low-attenuation plaque volume in the LDL <70 group was significantly lower than in the LDL-C >70 group (17.2 & PLUSMN; 90.9% vs 84.4 & PLUSMN; 162.6%, p = 0.020). Receiver oper-ating characteristic curve analysis demonstrated that the target LDL-C level for low-attenuation plaque volume regression was 64 mg/100 ml. In conclusion, noninvasive CCTA demonstrated that intensive LDL-C lowering in high-risk patients with ACS could potentially lead to plaque stabilization. & COPY; 2023 Elsevier Inc. All rights reserved. (Am J Cardiol 2023;204:84-91)
引用
收藏
页码:84 / 91
页数:8
相关论文
共 50 条
  • [41] Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease
    Hu, Gang
    Cui, Yadong
    Jousilahti, Pekka
    Sundvall, Jouko
    Girman, Cynthia J.
    Antikainen, Riitta
    Laatikainen, Tiina
    Tuomilehto, Jaakko
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2013, 20 (01) : 89 - 97
  • [42] Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes
    Lotta, Luca A.
    Stewart, Isobel D.
    Sharp, Stephen J.
    Day, Felix R.
    Burgess, Stephen
    Luan, Jian'an
    Bowker, Nicholas
    Cai, Lina
    Li, Chen
    Wittemans, Laura B. L.
    Kerrison, Nicola D.
    Khaw, Kay-Tee
    McCarthy, Mark I.
    O'Rahilly, Stephen
    Scott, Robert A.
    Savage, David B.
    Perry, John R. B.
    Langenberg, Claudia
    Wareham, Nicholas J.
    JAMA CARDIOLOGY, 2018, 3 (10) : 957 - 966
  • [43] Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions
    Zhang, Shuang
    Li, Zhi-Fan
    Shi, Hui-Wei
    Zhang, Wen-Jia
    Sui, Yong-Gang
    Li, Jian-Jun
    Dou, Ke-Fei
    Qian, Jie
    Wu, Na-Qiong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [44] Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy
    Couvert, Philippe
    Chapman, M. John
    Carrie, Alain
    PHARMACOGENOMICS, 2011, 12 (02) : 137 - 139
  • [45] Small Dense Low-Density Lipoprotein for Risk Prediction of Acute Coronary Syndrome
    Singh, Abhishek
    Puhan, Rajendra
    Pradhan, Akshyaya
    Ali, Wahid
    Sethi, Rishi
    CARDIOLOGY RESEARCH, 2021, 12 (04) : 251 - 257
  • [46] Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naive acute coronary syndrome
    Im, Jihaeng
    Kawada-Watanabe, Erisa
    Yamaguchi, Junichi
    Arashi, Hiroyuki
    Otsuki, Hisao
    Matsui, Yuko
    Sekiguchi, Haruki
    Fujii, Shinya
    Mori, Fumiaki
    Ogawa, Hiroshi
    Hagiwara, Nobuhisa
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [47] Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease
    Chieng, David
    Pang, Jing
    Ellis, Katrina L.
    Hillis, Graham S.
    Watts, Gerald F.
    Schultz, Carl J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 1019 - 1026
  • [48] An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals
    Buonvino, Camille
    Chopard, Romain
    Guillon, Benoit
    Puymirat, Etienne
    Farnier, Michel
    Ferrieres, Jean
    Krempf, Michel
    Bruckert, Eric
    Meneveau, Nicolas
    Schiele, Francois
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2020, 9 (08) : 879 - 887
  • [49] Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
    Packard, Chris
    Chapman, M. John
    Sibartie, Mahendra
    Laufs, Ulrich
    Masana, Luis
    HEART, 2021, 107 (17) : 1369 - 1375
  • [50] Effects on Coronary Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol with Statins
    Ferrieres, Jean
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2009, 9 (02) : 109 - 115